Kornimate/medical-research-clean huggingface dataset:
the effect of intraoperative intravenous lidocaine infusion on postoperative pain and recovery in children (< 7 years old) undergoing thoracoscopic surgery

Conditions: Pain Management After Surgery

Summary: this study aims to investigate the efficacy of intraoperative intravenous lidocaine infusion on postoperative pain management and recovery in pediatric patients undergoing thoracoscopic pulmonary resection.


Eligibility criteria:
inclusion criteria: * pediatric patients aged under 7 years undergoing thoracoscopic pulmonary resection exclusion criteria: * cardiac dysfunction requiring vasopressors or inotropic agents * atrioventricular block or bradycardia * liver or kidney dysfunction * hypersensitivity to local anesthetics

Keywords: pediatric thoracoscopic surgery pain control lidocaine
feasibility of the braingate2 neural interface system in persons with tetraplegia (bg-speech-02)

Conditions: Anarthria; Dysarthria; Tetraplegia; Spinal Cord Injuries; Amyotrophic Lateral Sclerosis; Brain Stem Infarctions; Locked-in Syndrome; Muscular Dystrophies

Summary: the goal of this study is to improve our understanding of speech production, and to translate this into medical devices called intracortical brain-computer interfaces (ibcis) that will enable people who have lost the ability to speak fluently to communicate via a computer just by trying to speak.

the goal is to develop a new way to help people who lose the ability to speak due to neurological conditions including als or stroke, using an implanted medical device called a "brain-computer interface". the implanted medical device measures the person's brain activity as they try to talk and outputs their intended speech. by bypassing the injured parts of the nervous system this way, we can observe how individual brain cells are involved in speaking and working together as a network, to produce speech, and we can learn to decipher this activity to output what the person is trying to say.

Eligibility criteria:
inclusion criteria: * between 18 and 80 years of age * clinical diagnosis of spinal cord injury, brainstem stroke, muscular dystrophy, amyotrophic lateral sclerosis or other motor neuron disorders * complete or incomplete tetraplegia (quadriplegia) * must live within a three-hour drive of the study site and geographically stable for at least 15 months after enrollment. (there are additional inclusion criteria) exclusion criteria: * visual impairment such that extended viewing of a computer monitor would be difficult even with ordinary corrective lenses * chronic oral or intravenous steroids or immunosuppressive therapy * other serious disease or disorder that could seriously affect ability to participate in the study (there are additional exclusion criteria)
ultrasound-guided continuous proximal adductor canal vs continuous femoral nerve block for postoperative pain control and rehabilitation following total knee arthroplasty

Conditions: Total Knee Arthroplasty

Summary: the purpose of the study is to compare continuous femoral nerve block with continuous proximal adductor canal block for postoperative pain control and rehabilitation.

patients meeting the criteria: american society of anesthesiologists (asa) class i and ii, that are scheduled for elective total knee arthroplasty, will be recruited into the study. subjects will be randomized into 2 groups: those who will receive a continuous proximal adductor canal block (acb) and those who will receive a continuous femoral nerve block (fnb).

Eligibility criteria:
inclusion criteria: * patients with an american society of anesthesiologists physical status classification system (asa) score of 1 or 2 that are healthy without systemic disease or have mild systemic disease, respectively. * the patient will need to be able to have decision-making capacity and ability to consent for the study. exclusion criteria: * patients with an american society of anesthesiologists physical status classification system (asa) score greater than 2. * patients unable to have decision-making capacity and ability to consent for the study.

Keywords: a continuous proximal adductor canal block (acb) continuous femoral nerve block (fnb)
gastric us in icu patient

Conditions: Critical Illness; Surgery; Aspiration Pneumonia

Summary: this is a case series study using gastric ultrasound in critically ill patients to quantify gastric residual volumes to compare the efficacy of different npo protocols.


Eligibility criteria:
inclusion criteria: * patients age 18 or older, admitted to the icu, requiring general anesthesia or sedation for a procedure with a pre-existing, cuffed endotracheal or tracheostomy tube. most patients admitted to the icu would be unable to consent. exclusion criteria: * known upper gastrointestinal anatomical problem that would prevent accurate estimation of gastric volume, gastric perforation, pregnancy beyond the first trimester. * lack of a pre-existing, cuffed endotracheal or tracheostomy tube.

Keywords: npo protocols intensive care unit gastric ultrasound ultrasound surgical intensive care unit npo nasogastric tube orogastric tube enteral nutrition parenteral nutrition gastric residual volume aspiration critical illness nutrition
safety and effectiveness study of duloxetine hcl in women of different backgrounds with stress urinary incontinence who may also have other various medical conditions.

Conditions: Stress Urinary Incontinence

Summary: the purpose of the trial is to study the safety and effectiveness of duloxetine hcl in women of different backgrounds with stress urinary incontinence who may also have other various medical conditions.


Eligibility criteria:
inclusion criteria: * women age 18 years or older who have for the 3 months prior to study entry at least 1 episode per week of stress urinary incontinence or stress predominant urinary incontinence defined as twice as many stress as urge urinary incontinence episodes per week. * women of non-childbearing potential by reason of hysterectomy, surgical or natural menopause. women of childbearing potential should be using a medically accepted means of contraception. * must provide informed consent. * must not have urinary tract infection at screening. exclusion criteria: * sensitivity to duloxetine * unstable medical conditions * pregnancy * acute liver damage * suicidal in the opinion of the investigator
clinical evaluation of injectable platelet rich fibrin with connective tissue graft for the treatment of deep gingival recession defects.

Conditions: Gingival Recession

Summary: aim: the aim of this study was to determine whether the combined connective tissue graft (ctg) with injectable platelet rich fibrin (i-prf) with coronally advanced flap (caf) improved root coverage of deep miller class i or ii gingival recessions compared to ctg alone with caf. methods: seventy-two patients with miller class i and ii gingival recessions were enrolled. thirty-six patients were randomly assigned to the test group (caf+ctg+i-prf) or control group (caf+ctg). clinical evaluations were made at 6 months


Eligibility criteria:
inclusion criteria: * ≥19 years of age, * periodontally and systemically healthy, * fmps and fmbs \<15%, * presence of deep miller class i and ii gingival recession defect (≥3 mm in depth) at the buccal aspect of incisors, exclusion criteria: smoking, * contraindications for surgery, * presence of recession defects associated with caries, deep abrasion, restoration or pulpal pathology.

Keywords: connective tissue graft
comperative trial between an accommodative iol and monofocal iol

Conditions: CATARACT SURGERY

Summary: a comparison of two intraocular lenses in regard of accommodative power.

a new accommodating iol (acuity ltd, israel) will be compared with alcon's acrysof for 1 year for visual acuity and distance and near best corrected visual acuity.

Eligibility criteria:
inclusion criteria: * age between 30 and 65 * required cataract operation in one or both eyes * bcva potetial at least 20/30 * clear intraoccular media * willing to participate in study as evidenced by signing a written informed consent exclusion criteria:main * prior surgery at the selected eye * no light perception or poor potential for improvement * phacodonesis and damaged zonules * pupil size at least 6 mm. * history of uveitis * macular disease decreasing vision below 20/30 * amblyopia * axial length shorter than 21 mm and longer than 25 mm
the effect of antibiotic prophylaxis associated with dental implant surgery

Conditions: Infection Control; Antibiotic Prophylaxis

Summary: the overall aim of the study is to investigate whether routine administration of antibiotic prophylaxis 1 hour prior to implant surgery may prevent postoperative infection and implant loss in healthy or substantially healthy patients (asa class 1 and class 2).

the prevalence of bacteria resistant to antibiotics is increasing and there is a correlation between high consumption of antibiotics and high incidence of antibiotic resistance. it is therefore important to reduce the prescription of antibiotics. antibiotics in dental care are used to treat oral infections as well as to prevent infections associated with surgical procedures. an example of the latter is antibiotic prophylaxis associated with dental implant surgery in order to reduce the risk of postoperative infection that can lead to loss of implant.the study will be conducted as a multicenter placebo-controlled randomized clinical trial. eligible patients will be asked for participation and those who leave oral and written information will be included in the study. patients included will be allocated to either active treatment (antibiotic prophylaxis) or placebo. both clinicians and patients will be blinded to group affiliation. a total of 10 clinicians in 8 centers in the south of sweden have agreed to participate and each clinicians will be allowed to use the implants and routines that they usually work with. specific aims of the study are to test the following hypotheses: 1. there is no difference in proportion of patients with early implant losses in patients receiving 2 g of amoxicillin preoperatively and patients receiving identical placebo tablets. 2. there is no difference in proportion of patients with early infections between patients receiving 2 g of amoxicillin preoperatively and patients receiving identical placebo tablets. 3. there is no difference in infections (within 3-6 months postoperatively) between patients receiving 2 g of amoxicillin preoperatively and patients receiving identical placebo tablets. if it appears that antibiotic prophylaxis does not lead to any risk reduction, this result may provide a basis for guidelines rejecting antibiotic prophylaxis in dental implant surgery.

Eligibility criteria:
inclusion criteria: * requirement for dental implant placement * over 18 years of age exclusion criteria: * immunosuppressed or immunocompromised * affected by not controlled diabetes * serious or severe systemic disease (asa classification \> 2) * previous radiotherapy to the head or neck area * ongoing acute or chronic infection in the oral cavity * ongoing treatment with antibiotics * hypersensitivity to penicillin * previous or ongoing treatment with bisphosphonates * in need of major bone augmentation * planned direct loading or early loading (within 2 weeks) of the implant

Keywords: dental implants, antibiotic prophylaxis
alcohol dependency study: combining medication treatment for alcoholism

Conditions: Alcoholism

Summary: the purpose of this study is to learn whether ondansetron and topiramate either alone or in combination is safe and effective in the treatment of alcohol dependence. this 13 week out-patient clinical trial is randomized, double-blind, and placebo-controlled. there are post-study follow up visits 1, 2 and 3 months after the end of the study. participants will receive ondansetron and topiramate either alone or in combination or a placebo coupled with psychotherapy.

this study is a 13 week clinical trial. during the 13 weeks participants receive placebo, ondansetron and topiramate alone or in combination. during the 13 weeks participants come to an outpatient clinic to receive the study medication, physical checks, and cognitive behavioral therapy. the duration of the weekly visit is 3 hours. there is a 1, 2, and 3 month post-study follow up visit. screening for this study is initially done over the telephone and takes 15-20 minutes. if there is nothing found to make someone ineligible to participate, they come to the out-patient clinic for a more thorough in-clinic screening.

Eligibility criteria:
inclusion criteria: * current diagnosis of alcohol dependence and drinking greater than or equal to 14 alcohol drinks/week for women and greater than or equal to 21 alcohol drinks/week for men in the last 30 days. * provide a written, informed consent. * good physical health and must weigh within at least 40 kg and no more than 140 kg. * literate in english and able to read, understand, follow instructions, and complete questionnaires accurately. * willingness to participate in behavioral treatments for alcoholism. * provide evidence of stable residence in the last month prior to enrollment in the study and have no plans to move during the next three months. exclusion criteria: please contact site for additional information

Keywords: alcoholism alcohol addiction
oral chinese herbal medicine concurrent with secukinumab for severe plaque psoriasis

Conditions: Psoriasis

Summary: the aim of this study is to determine whether oral chinese herbal medicine in combination secukinumab is effective and safe in the treatment of severe psoriasis.

the aim of this study is to determine whether oral chinese herbal medicine in combination with secukinumab is effective and safe in the treatment of severe psoriasis. eligible participants will be treated with oral chinese herbal medicine and secukinumab concurrently. no controlled group will be set up in this trial. the primary outcome is time to relapse. secondary outcomes include psoriasis area and severity index (pasi) 75/90, pasi score reduction rate, physician's global assessment (pga) score, body surface area (bsa) score, visual analogue scale (vas) score, dermatology life quality index (qlqi) and skindex 16.

Eligibility criteria:
inclusion criteria: 1. psoriasis area and severity index (pasi) score≥10 2. meet the requirement of using secukinumab; without the history of inflammatory bowel disease (ibd) 3. written/signed informed consent exclusion criteria: 1. unsuitable for the treatment of secukinumab
a phase ii study of oral jak1/jak2 inhibitor inc424 in adult patients with relapsed/refractory classical hodgkin's lymphoma

Conditions: Hodgkin's Lymphoma

Summary: phase ii study to assess the efficacy of 6 cycles of oral jak1/2 inhibitor ruxolitinib in patients with advanced hodgkin's lymphoma for whom no curative option is available.


Eligibility criteria:
inclusion critera: * patients ≥ 18 years with classical hl relapsing or refractory after at least 1 prior systemic therapy. patients must have relapsed after high-dose therapy with asct, or have been deemed ineligible for high-dose therapy with asct * ecog performance status ≤ 3 * measurable nodal disease: 1 cm in the longest transverse diameter and clearly measurable in at least two perpendicular dimensions, as determined by ct scan (mri is allowed only if ct scan cannot be performed). * patient has the following laboratory values: * absolute neutrophil count (anc) ≥ 1.0 x 10\^9/l \[si units 1.0 x 10\^9/l\] * platelet count ≥ 75 x 10\^9/l\] * serum creatinine ≤ 1.5 x upper limit of normal (uln) * serum bilirubin ≤ 1.5 x uln (or ≤ 3.0 x uln, if patient has gilbert syndrome) * ast/sgot and/or alt/sgpt ≤ 2.5 x uln or ≤ 5.0 x uln if the transaminase elevation is due to liver disease involvement * signed written informed consent * life expectancy ≥ 3 months * corrected qt interval ≤ 450 msec * men and women of childbearing potential must agree to use an adequate method of contraception during the study treatment and for at least 1 week after the last study drug administration * the patient must be covered by a social security system (for inclusions in france) exclusion criteria: * previous treatment with ruxolitinib or another jak inhibitor * contraindication to ruxolitinib * patient received chemotherapy or radiotherapy or any investigational drug within 14 days prior to starting study drug or whose side effects of such therapy have not resolved to ≤ grade 1 * patient treated with allogeneic hematopoietic stem cell transplant who is currently on, or has received immunosuppressive therapy within 90 days prior to start of screening and/or have ≥ grade 2 graft versus host disease (gvhd). * patient with prior history of another active primary malignancy ≤ 2 years before study entry, with the exception of non-melanoma skin cancer, and carcinoma in situ of uterine cervix * any serious active disease or co-morbid medical condition that, according to the investigator's decision, will substantially increase the risk associated with the subject's participation in the study. * uncontrolled infectious disease, including active hbv infection defined by either detection of hbs antigen or presence of anti hbc antibody without detectable anti hbs antibody. * hiv, hcv or htlv serology positivity and/or documented infection with active hepatitis b * prior history of cns involvement with lymphoma * pregnant or lactating woman * adult patient unable to provide informed consent because of intellectual impairment, any serious medical condition, laboratory abnormality or psychiatric illness.

Keywords: multicenter, single arm and opened label phase ii study
liberal versus restrictive transfusion guidelines for preterm infants

Conditions: Infant, Premature; Anemia; Intracranial Hemorrhages; Leukomalacia, Periventricular; Apnea

Summary: the purpose of this study was to determine whether restrictive guidelines for red blood cell (rbc) transfusions for preterm infants can reduce the number of transfusions without adverse consequences.

design, setting, and patients. we enrolled 100 hospitalized preterm infants with birth weights 500 to 1300 g into a randomized clinical trial comparing two levels of hematocrit threshold for rbc transfusion. intervention. the infants were randomly assigned to either the liberal or the restrictive transfusion group. for each group, transfusions were given only when the hematocrit fell below the assigned value. in each group, the transfusion thresholds decreased with improving clinical status. main outcome measures. we recorded the number of transfusions, the number of donor exposures, and various clinical and physiological outcomes. results. infants in the liberally transfused group received more rbc transfusions, mean 5.2 (sd 4.5) vs 3.3 (sd 2.9) in the restrictive transfusion group (p=0.025). however, the number of donors to whom the infants were exposed was not significantly different, mean 2.8 (sd 2.5) vs 2.2 (sd 2.0). there was no difference between the groups in the percentage of infants who avoided transfusions altogether, 12% in the liberal transfusion group vs 10% in the restrictive group. infants in the restrictive group were more likely to have intraparenchymal brain hemorrhage or periventricular leukomalacia (p=0.012), and they had more frequent episodes of apnea (p=0.004), including both mild and severe episodes.

Eligibility criteria:
inclusion criteria: * preterm infant * birth weight 500-1300 grams exclusion criteria: * alloimmune hemolytic disease * congenital heart disease * other major birth defect requiring surgery * chromosomal abnormality * thought to be facing imminent death * parental philosophical or religious objections to transfusion * more than 2 transfusions before enrollment * participation in other research study with potential impact on this study

Keywords: transfusions erythrocyte anemia brain infant, premature
excel drug-eluting stent pilot clinical registry

Conditions: Coronary Stenosis

Summary: the trial aims to evaluate long-term efficiency of excel stent in the inhibition of restenosis as well as the safety after the cessation of the 6-month anti-platelet drug treatment.

30-day, 6-month, and 12-month clinical follow-up and 6 to 9-month ivus or sca follow-up to measure long-term efficiency of excel stent in the inhibition of restenosis as well as the safety after the cessation of the 6-month anti-platelet drug treatment.

Eligibility criteria:
inclusion criteria: * patients who should fulfill with criteria of implanting excel stents. * each patient enrolled is only allowed to implant excel stents. * each patient are not allowed to be implanted more than 6 excel stents.also, 3 over-lapped stents are not allowed to be implanted in the same vessel(3-5mm overlapping needed; length of stents totally are not allowed to be over 80mm; fully post-dilated is essential for overlapping). * patients acknowlegement to the trial is essential. exclusion criteria: * ami withine 1 week. * patients who do not suitable to excel stenting.(for example, non-tolerant to anti-platelet drug or cardiac/non-cardiac surgery undergoing recently.) * patients who have multiple branch lesions can not apply single excel stenting. * patients who refuse to sign the trial acknowledgement. * patients with intra-stent restenosis.
modulation of endothelial dysfonction using vitamin c in septic shock patients

Conditions: Septic Shock

Summary: compare the microcirculatory reactivity before and after a 30-minute intravenous infusion of 40 mg/kg vitamin c and evaluate intra-individual variation of hemodynamic parameters between t0 and t1.

this is a transversal study allowing to compare the microcirculatory reactivity before and after a 30-minute intravenous infusion of 40 mg/kg vitamin c. design: • a monocentric, open-label, transversal study sample size : 30 patients assessement: between 6 hours and 24 hours after admission, the patient will be included after collection of the non opposition. there will be two evaluation times: t0 before the start of vitamin c's perfusion, and t1: 1 hour after the end. no interim analysis is planned. analysis will be performed at the end of the study after data review and freezing of data base.

Eligibility criteria:
inclusion criteria: * age \> 18 years * septic shock patient, reanimated and stabilized defined as: * patients with sepsis (suspected infection + 2 sofa points) according to the latest international and the need to receive norepinephrine to maintain an average blood pressure above 65 mmhg * patient supported for at least 6 hours, necessary for diagnostic management and hemodynamic optimization according to international standards and for less than 24 hours to limit confounding factors related to prolonged reanimation (sedation) and the empowerment of organ failures in general and vascular in particular. hemodynamic stabilization will be defined as no increase in norepinephrine dosages exclusion criteria: * pregnant or nursing women, * participation in another intervention research involving the human person or exclusion period following a previous research involving the human person * ward or curative patient * moribund patient * estimated life expectancy less than 1 month

Keywords: endothelial dysfunction vitamin c septic shock microcirculatory effects hemodynamic effects